{"id":"cladribine-pill","safety":{"commonSideEffects":[{"rate":null,"effect":"Lymphopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cladribine is a deoxyadenosine analog that is phosphorylated intracellularly and incorporated into DNA, causing strand breaks and apoptosis. It preferentially affects lymphocytes due to their high deoxycytidine kinase activity and low 5'-nucleotidase activity, making it useful in lymphoproliferative and autoimmune disorders.","oneSentence":"Cladribine is a purine nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, leading to selective depletion of lymphocytes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:45:04.995Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple sclerosis (relapsing-remitting)"},{"name":"Hairy cell leukemia"},{"name":"Chronic lymphocytic leukemia"}]},"trialDetails":[{"nctId":"NCT03477500","phase":"PHASE3","title":"Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2018-03-21","conditions":"Multiple Sclerosis","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Mavenclad"],"phase":"phase_3","status":"active","brandName":"Cladribine Pill","genericName":"Cladribine Pill","companyName":"Haukeland University Hospital","companyId":"haukeland-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"The Cladribine Pill is a small molecule that inhibits DNA, classified as a DNA inhibitor. It is being studied as a treatment for Multiple Sclerosis, with clinical trials comparing it to other treatments such as Alemtuzumab and autologous hematopoietic stem cell transplantation.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":"2017-08-22T00:00:00.000Z","mah":"Merck Europe B.V.","brand_name_local":"Mavenclad","application_number":"EMEA/H/C/004230"}],"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}